

Agneta Edberg Appointed as Chairperson of Amferia AB

MÖLNDAL, July 28, 2022

Amferia AB is happy to announce the appointment of Agneta Edberg as the new Chairperson of the company's Board of Directors. Agneta has extensive background from the life-science industry bringing knowledge and experience for the continued growth of Amferia. The company is now preparing to launch the first product within Animal Health during 2022.



Agneta has a solid background from the global Life science and Medtech field spanning over 30 years in leading roles such as; Sales & Marketing Director of Pharmacia (Pfizer), Senior VP and CEO of Mylan Nordic Pharmaceuticals, CEO of NM Pharma and more recently as the COO of Bactigaard that manufactures a variety of antimicrobial device. Today, she works on the Board of cutting-edge life-science SME's guiding the companies for future success. Agneta's extensive knowledge in the life science industry will be important for Amferia's scale-up journey in both human and animal wound care.

Anand Kumar Rajasekharan, CEO of Amferia – "It is an honour to work with Agneta, whose impressive knowledge of the field and guidance greatly strengthens Amferia's position as a competent and cutting-edge SME. We look forward to jointly achieve the upcoming key milestones such as the first product launch for animal health, FDA and CE regulatory processes for human health and establishing a successful sales and marketing foundation for Amferia."

Agneta Edberg – "Amferia is a company every board person wishes to work for. The technology offers a paradigm shift in wound care with nontoxic properties still killing bacteria, even the resistant ones. In a world where antimicrobial resistance is an increasing challenge to humanity, I am grateful to be a part of reducing that threat"

About Amferia:

Amferia was founded in 2018 as a spin-off from the Applied Chemistry department of Chalmers University of Technology, Gothenburg, Sweden. Amferia's proprietary technology is a new and effective antimicrobial material that targets and rapidly kills bacteria upon contact, including numerous antimicrobial resistant bacteria like MRSA and MDR *E. Coli*.

The material is selective and targets only bacteria while being entirely nontoxic to human and animal cells. Today, the team has transformed this concept into a technology platform, with the first product being an antimicrobial wound care dressing for skin wound applications in human and animal health, supported by strong scientific data. Read more at www.amferia.com

= = =

For more information, please contact:

Anand Kumar Rajasekharan,

CEO, Amferia, +46 76 298 12 38

anandk@amferia.com